FilingReader Intelligence

Strides Pharma reports strong Q1 financial growth

July 29, 2025 at 07:30 AM UTC•By FilingReader AI

Strides Pharma Science reported Q1FY26 revenue of ₹11,197m, EBITDA of ₹2,181m, and operational PAT of ₹1,140m. Gross margin improved to 60.3%.

Net debt decreased to ₹14,958m despite currency impact and capital expenditure.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Strides Delivers a strong Q1 FY 2026 with Rs.11,197 million Revenue, Rs. 2,181 million EBITDA and Rs. 1,140 million Operational PAT.July 29, 2025 at 07:11 AM UTC

Supplementary Source Documents

Allotment of shares under the ESOP SchemeJuly 29, 2025 at 07:18 AM UTC

Amendment to code of fair disclosure of UPSIJuly 29, 2025 at 07:14 AM UTC

STRIDES PHARMA SCIENCE

BSE:STAR•Bombay Stock Exchange

RSS feed for STRIDES PHARMA SCIENCE

News Alerts

Get instant email alerts when STRIDES PHARMA SCIENCE publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →